Abstract
Cancer cells are characterized by reprogramming of energy metabolism. Over the last decade, understanding of the metabolic changes that occur in cancer has increased dramatically, with great interest in targeting metabolism for cancer therapy. Pyruvate kinase isoenzyme type M2 (abbreviations: PKM2, M2-PK) plays a key role in modulating glucose metabolism to support cell proliferation. PKM2, like other PK isoforms, catalyzes the last energy-generating step in glycolysis, but is unique in its capacity to be regulated. PKM2 is regulated at several cellular levels, including gene expression, alternative splicing and post-translational modification. In addition, PKM2 is regulated by key metabolic intermediates and interacts with more than twenty different proteins. Hence, this isoenzyme is an important regulator of glycolysis, and additionally functions in other novel roles that have recently emerged. Recent evidence indicates that intervening with the complex regulatory network of PKM2 has severe consequences on tumor cell proliferation, indicating the potential of this enzyme as a target for tumor therapy.
Keywords: Pyruvate Kinase M2 (PKM2), Cancer therapeutics, Cancer Metabolism, PKM2 regulation, alternative splicing, post-translational modification, glycolysis, network.
Current Pharmaceutical Design
Title:Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Volume: 20 Issue: 15
Author(s): Vibhor Gupta, Kathryn E. Wellen, Sybille Mazurek and Rameshwar N. K. Bamezai
Affiliation:
Keywords: Pyruvate Kinase M2 (PKM2), Cancer therapeutics, Cancer Metabolism, PKM2 regulation, alternative splicing, post-translational modification, glycolysis, network.
Abstract: Cancer cells are characterized by reprogramming of energy metabolism. Over the last decade, understanding of the metabolic changes that occur in cancer has increased dramatically, with great interest in targeting metabolism for cancer therapy. Pyruvate kinase isoenzyme type M2 (abbreviations: PKM2, M2-PK) plays a key role in modulating glucose metabolism to support cell proliferation. PKM2, like other PK isoforms, catalyzes the last energy-generating step in glycolysis, but is unique in its capacity to be regulated. PKM2 is regulated at several cellular levels, including gene expression, alternative splicing and post-translational modification. In addition, PKM2 is regulated by key metabolic intermediates and interacts with more than twenty different proteins. Hence, this isoenzyme is an important regulator of glycolysis, and additionally functions in other novel roles that have recently emerged. Recent evidence indicates that intervening with the complex regulatory network of PKM2 has severe consequences on tumor cell proliferation, indicating the potential of this enzyme as a target for tumor therapy.
Export Options
About this article
Cite this article as:
Gupta Vibhor, Wellen E. Kathryn, Mazurek Sybille and Bamezai K. Rameshwar N., Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention, Current Pharmaceutical Design 2014; 20 (15) . https://dx.doi.org/10.2174/13816128113199990484
DOI https://dx.doi.org/10.2174/13816128113199990484 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy
Current Pharmaceutical Design Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets The Dual Role of Nitric Oxide in Glioma
Current Pharmaceutical Design Recent Advancements in Liposome-Based Strategies for Effective Drug Delivery to the Brain
Current Medicinal Chemistry Ectodomain Shedding and Regulated Intracellular Proteolysis in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry HSP60 as a Drug Target
Current Pharmaceutical Design Gene Therapy of Cancer Based on Interleukin 12
Current Gene Therapy Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Models of HIV-1 Persistence in the CD4+ T Cell Compartment: Past, Present and Future
Current HIV Research The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
Current Cancer Drug Targets Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Recent Advances in Efficacy of using Doxorubicin Gold Nanoparticles for Chemo-, Radio-, Photothermal, and Photodynamic Therapy
Current Drug Delivery Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Current Pharmaceutical Design Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Interrelation of Major Depression and Antidepressant Transcriptomics
Current Psychopharmacology